The 3D bioprinting industry is expected to grow at a significant Compound Annual Growth Rate (CAGR) of 12.6% between 2023 and 2033, according to a ground-breaking analysis. This will increase the market’s valuation from an astounding US$ 2 billion in 2023 to an expected US$ 6.5 billion by 2033.
Key Drivers of Market Surge:
- Addressing Organ Shortages: The market is responding to the critical issue of organ shortages by providing innovative solutions to overcome the challenges posed by the limited availability of organ donors.
- Aging Population and Respiratory Challenges: With a rising geriatric population grappling with chronic respiratory diseases, the demand for advanced healthcare solutions such as 3D bioprinting is witnessing a substantial upswing.
- Investment in Research and Technological Advancements: The surge in investments in Research and Development, coupled with ongoing technological advancements in the healthcare sector, is driving the evolution of 3D bioprinting. This influx of resources is fostering the development of cutting-edge solutions that have the potential to reshape the landscape of healthcare.
Get a Sample Copy of the Report:https://www.futuremarketinsights.com/reports/sample/rep-gb-808
The 3D bioprinting market is not just a testament to technological innovation but also a beacon of hope for addressing critical healthcare challenges. As we advance towards 2033, the market is not only set to transform the healthcare industry but also promises significant contributions in overcoming organ shortages and improving the quality of life for individuals with respiratory ailments.
Investors, stakeholders, and healthcare professionals alike are encouraged to delve into this transformative report, exploring the immense potential and future prospects within the dynamic realm of 3D bioprinting. Embrace the future of healthcare through the lens of innovation and technological breakthroughs.
Medical Device Manufacturers Taking the Lead:
In the dynamic landscape of 3D bioprinting, medical device manufacturers emerge as the primary end-users, driving a remarkable surge in demand. With a compelling need for advanced implants to facilitate effective treatments, this segment is anticipated to capture over 45% of the market share throughout the forecast period, according to projections by FMI.
The symbiotic relationship between medical device manufacturers and leading hospitals is a key contributor to this surge. Strategic collaborations empower manufacturers to meet the rising demand for 3D bioprinting systems, especially when hospitals issue tenders. Bulk orders for these innovative systems become commonplace, given their integral role in producing implants and other devices that complement the 3D bioprinting process.
Start-ups Pioneering Breakthroughs:
In the realm of 3D bioprinting, start-ups are rewriting the narrative by pushing the boundaries of innovation. One such trailblazer is Cyfuse Biomedical, making significant strides in medical treatments through its revolutionary 3D engineering technology. The company’s flagship creation, the BIO 3D Printer, known as Regenova, stands as a testament to cutting-edge robotics in tissue fabrication.
Regenova, a state-of-the-art robotic system, enables the fully automated production of 3D artificial tissues using living cells. This breakthrough not only signifies a leap forward in tissue engineering but also underscores the transformative potential of 3D bioprinting in healthcare. Notably, in January 2021, Cyfuse Biomedical secured an undisclosed investment from Fujimoro Kogyo, highlighting the industry’s recognition and support for such groundbreaking initiatives.
Start-ups Redefining Healthcare Possibilities:
Beyond conventional applications, start-ups in the 3D bioprinting arena are charting new territories. They are not only creating functional human tissues through 3D bioprinting but are also leveraging holographic tissue printing technology for rapid antibody discovery. This approach holds promise for in-vitro human disease solutions, offering a glimpse into the future of personalized medicine and advanced healthcare treatments.
As the 3D bioprinting landscape continues to evolve, these innovative endeavors by both established medical device manufacturers and dynamic start-ups underscore the transformative potential of this technology in shaping the future of healthcare. The collaboration between industry leaders and nimble innovators sets the stage for groundbreaking advancements, promising a new era of medical possibilities.
Manufacturers Dig Deeper into Product Development, make use of High-performance Metals:
The key players operating in the 3D bioprinting market are currently strengthening their materials portfolio. This is mainly done by adding new metals to the product portfolio. Apart from that, technological upgradation is also being done by the key players to simplify the processes.
For example, 3D Systems announced the addition of two new materials in November 2022: Certified HX and Certified CuCr2.4 to its materials portfolio. They come with a variety of applications, which include energy, industrial gas turbine, heat management, and cooling applications.
Some of the recent developments are:
- In November 2022, 3D Systems expands its selective laser sintering portfolio through a strategic partnership with Wematter.
- In November 2022, GE Healthcare and Ulrich Medical announce an agreement to offer a branded multi-dose contrast media injector in the US.
Key Players:
| Company | Description |
|---|---|
| 3D Systems | 3D systems launched the 3D printing industry in 1996 and have been the industry leader since then. The portfolio of hardware, software, and materials solutions ranges from plastics to metals and is backed by industry-specific engineering expertise. The company has been taking a consultative, application-focused approach to solving design and production challenges. The combination of solution, expertise, and innovation helps customers defy conventional manufacturing limitations. Thus, the focus is on maximizing the value of additive manufacturing. The company provides operations in more than 68 countries through a partner network and solution sales specialists. |
| GE Healthcare | Being the global medical technology, pharmaceutical diagnostics, and digital solutions innovator, GE Healthcare enables clinicians to make informed decisions. The company has been making use of intelligent devices, data analytics, applications, and services, supported by the Edison Intelligence Platform. The company has been relentlessly working to solve the greatest challenges in healthcare. Thus, GE Healthcare is not only building a healthy future but living the purpose to create a world where healthcare has no limits. By accepting diverse perspectives, the company is better equipped to help improve lives in the moments that matter and build a healthier world. |
| ExOne | For more than two and a half decades, ExOne has been on a mission to deliver powerful 3D printers. These printers have been designed to solve the toughest problems and enable world-changing innovations. The 3D printing systems quickly transform granular materials into precision metal casting molds and cores. ExOne is innovating on a continuous basis to ensure that 3D printing applications set the tone for advancement. From providing 3D printing for prototyping and casting to production lines, ExOne printers serve diverse applications in a variety of industries. |
Other companies profiled: Electro Optical Systems, Renishaw plc.
3D Bioprinting Market Segmentation
By Technology:
- Stereolithography,
- Selective Laser Sintering,
- Electron Beam Melting,
- Fused Deposition Modeling,
- Laminated Object Manufacturing,
- Inkjet Printing,
- Multi-phase Jet Solidification
By Application:
- Surgical Simulation and Training Models,
- Prosthetic Devices,
- Tissue Engineering and Regenerative Medicine,
- Orthopedic Implants,
- Dental Implants,
- Medical Sensors,
- Others
By End User:
- Medical Device Manufacturers,
- Pharmaceutical Companies,
- Research & Academic Institutions,
- Contract Research Organizations
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube